Argen-X

ARGX.BR · Moat type: REGULIERUNG

MoatScore

8/10

Fair Value

521 EUR (≈ 594.54 USD)

Margin of Safety

-46.7 %

Rating

BEOBACHTEN

Argen-X develops and commercializes monoclonal antibody therapies for treating severe autoimmune diseases, with the core product Efgartigimod being commercialized across global markets in various formulations (intravenous and subcutaneous), and revenue generated primarily through drug sales as well as license and milestone payments from partnerships.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.